Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2431760
Max Phase: Preclinical
Molecular Formula: C26H29BrClN3O3
Molecular Weight: 510.43
Molecule Type: Small molecule
Associated Items:
ID: ALA2431760
Max Phase: Preclinical
Molecular Formula: C26H29BrClN3O3
Molecular Weight: 510.43
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN[C@@H](C)C(=O)N[C@H]1CCc2ccccc2N(Cc2c(OC)ccc3cc(Br)ccc23)C1=O.Cl
Standard InChI: InChI=1S/C26H28BrN3O3.ClH/c1-16(28-2)25(31)29-22-12-8-17-6-4-5-7-23(17)30(26(22)32)15-21-20-11-10-19(27)14-18(20)9-13-24(21)33-3;/h4-7,9-11,13-14,16,22,28H,8,12,15H2,1-3H3,(H,29,31);1H/t16-,22-;/m0./s1
Standard InChI Key: NLXJDNKAIFMMCM-VPRHZQQDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 510.43 | Molecular Weight (Monoisotopic): 509.1314 | AlogP: 4.18 | #Rotatable Bonds: 6 |
Polar Surface Area: 70.67 | Molecular Species: BASE | HBA: 4 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 12.11 | CX Basic pKa: 8.60 | CX LogP: 4.07 | CX LogD: 2.84 |
Aromatic Rings: 3 | Heavy Atoms: 33 | QED Weighted: 0.52 | Np Likeness Score: -0.46 |
1. Donnell AF, Michoud C, Rupert KC, Han X, Aguilar D, Frank KB, Fretland AJ, Gao L, Goggin B, Hogg JH, Hong K, Janson CA, Kester RF, Kong N, Le K, Li S, Liang W, Lombardo LJ, Lou Y, Lukacs CM, Mischke S, Moliterni JA, Polonskaia A, Schutt AD, Solis DS, Specian A, Taylor RT, Weisel M, Remiszewski SW.. (2013) Benzazepinones and benzoxazepinones as antagonists of inhibitor of apoptosis proteins (IAPs) selective for the second baculovirus IAP repeat (BIR2) domain., 56 (20): [PMID:24083782] [10.1021/jm400731m] |
Source(1):